AIM
CRBP icon

Acrospire Investment Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Acrospire Investment Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-144
Closed -$36K – 2247
2016
Q4 		$36K Buy
+144
New +$33K 0.01% 1557

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Acrospire Investment Management's CRBP Position: Q1 2017 in Review

Acrospire Investment Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2017, closing a stake of 144 shares — an estimated $36K sold.

Acrospire Investment Management first reported a position in CRBP in Q4 2016 and held it in 1 quarter. The position peaked at $36K in Q4 2016. 54 funds tracked by Wall St. Rank hold CRBP as of Q1 2017.

  • Acrospire Investment Management reported no remaining Corbus Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 144 Corbus Pharmaceuticals shares in Q1 2017, an estimated $36K.
  • Acrospire Investment Management first reported a position in Corbus Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Corbus Pharmaceuticals position peaked at $36K in Q4 2016.
  • 54 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.